Kronos Bio (KRON) Competitors

Kronos Bio (NASDAQ:KRON) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.

Is KRON or SLDB more profitable?

Solid Biosciences has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Solid Biosciences' return on equity of -58.75% beat Kronos Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kronos Bio	-867.66%	-64.55%	-48.18%
Solid Biosciences	N/A	-58.75%	-47.84%

Does the media favor KRON or SLDB?

In the previous week, Kronos Bio had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for Kronos Bio and 7 mentions for Solid Biosciences. Kronos Bio's average media sentiment score of -0.19 beat Solid Biosciences' score of -0.43 indicating that Kronos Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kronos Bio	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Solid Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, KRON or SLDB?

Kronos Bio has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.

Do analysts rate KRON or SLDB?

Kronos Bio currently has a consensus price target of $1.63, suggesting a potential upside of 88.95%. Solid Biosciences has a consensus price target of $15.14, suggesting a potential upside of 205.30%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Kronos Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kronos Bio	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22

Which has preferable valuation and earnings, KRON or SLDB?

Solid Biosciences has higher revenue and earnings than Kronos Bio. Solid Biosciences is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kronos Bio	$6.29M	8.25	-$112.67M	-$1.43	-0.60
Solid Biosciences	$8.09M	24.50	-$96.01M	-$3.04	-1.63

Do insiders & institutionals believe in KRON or SLDB?

64.1% of Kronos Bio shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 24.4% of Kronos Bio shares are owned by insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community favor KRON or SLDB?

Solid Biosciences received 243 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 68.39% of users gave Solid Biosciences an outperform vote while only 65.63% of users gave Kronos Bio an outperform vote.

Company	Underperform	Outperform
Kronos Bio	Outperform Votes 21 65.63%	Underperform Votes 11 34.38%
Solid Biosciences	Outperform Votes 264 68.39%	Underperform Votes 122 31.61%

Summary

Solid Biosciences beats Kronos Bio on 14 of the 19 factors compared between the two stocks.